CytomX Therapeutics's total assets for Q4 2024 were $120.53M, a decrease of -13.27% from the previous quarter. CTMX total liabilities were $120.99M for the fiscal quarter, a -25.51% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.